Physician profile
Frank L Carter
NPI 1164464087
$3,373.85
in general payments reported to CMS, 2019-2025
35 companies · $436 in 2025
The $436 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $376 · 2020: $441 · 2021: $627 · 2022: $486 · 2023: $558 · 2024: $449 · 2025: $436.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,443.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,443.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $359.49 | 2019-2024 | |
| Abbvie INC. | $358.47 | 2021-2025 | Vraylar |
| Novo Nordisk INC | $288.14 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Amgen INC. | $187.73 | 2019-2025 | Repatha, Otezla, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $170.45 | 2021-2025 | |
| Lilly USA, LLC | $169.69 | 2019-2025 | Mounjaro, Zepbound |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $166.51 | 2020-2025 | Xifaxan, Trulance |
| Astrazeneca Pharmaceuticals Lp | $133.83 | 2019-2025 | Farxiga |
| Amarin Pharma, INC. | $123.62 | 2020-2021 | |
| Boston Scientific Corporation | $120.87 | 2020-2025 | Wavewriter Alpha Prime 16 |
| Dexcom, INC. | $111.54 | 2022-2024 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $110.90 | 2019-2021 | |
| Allergan, INC. | $110.54 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $110.34 | 2021-2024 | Rexulti |
| Esperion Therapeutics, INC. | $101.61 | 2020-2021 |
Show all 35 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frank Carter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.